WO2001042467A3 - Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - Google Patents

Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer Download PDF

Info

Publication number
WO2001042467A3
WO2001042467A3 PCT/US2000/033312 US0033312W WO0142467A3 WO 2001042467 A3 WO2001042467 A3 WO 2001042467A3 US 0033312 W US0033312 W US 0033312W WO 0142467 A3 WO0142467 A3 WO 0142467A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
compositions
methods
cervical cancer
genes
Prior art date
Application number
PCT/US2000/033312
Other languages
French (fr)
Other versions
WO2001042467A2 (en
Inventor
Robert Schlegel
James Deeds
Allison Berger
Xumei Zhao
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to AU20742/01A priority Critical patent/AU2074201A/en
Publication of WO2001042467A2 publication Critical patent/WO2001042467A2/en
Publication of WO2001042467A3 publication Critical patent/WO2001042467A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of cervical cancer.
PCT/US2000/033312 1999-12-08 2000-12-08 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer WO2001042467A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20742/01A AU2074201A (en) 1999-12-08 2000-12-08 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16968199P 1999-12-08 1999-12-08
US60/169,681 1999-12-08
US17135099P 1999-12-21 1999-12-21
US60/171,350 1999-12-21
US18931500P 2000-03-14 2000-03-14
US60/189,315 2000-03-14
US20379100P 2000-05-12 2000-05-12
US60/203,791 2000-05-12
US21060000P 2000-06-09 2000-06-09
US60/210,600 2000-06-09
US22011400P 2000-07-21 2000-07-21
US60/220,114 2000-07-21

Publications (2)

Publication Number Publication Date
WO2001042467A2 WO2001042467A2 (en) 2001-06-14
WO2001042467A3 true WO2001042467A3 (en) 2002-09-12

Family

ID=27558590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033312 WO2001042467A2 (en) 1999-12-08 2000-12-08 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Country Status (2)

Country Link
AU (1) AU2074201A (en)
WO (1) WO2001042467A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US20030144225A1 (en) * 2001-12-28 2003-07-31 Karras James G. Antisense modulation of macrophage inflammatory protein 3-alpha expression
EP1623991A3 (en) * 1999-09-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001238144A1 (en) * 2000-02-09 2001-08-20 Agensys, Inc. 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2002002759A2 (en) * 2000-06-29 2002-01-10 Millennium Pharmaceuticals, Inc. A human alpha/beta hydrolase family member (32225) and uses thereof
US20020102641A1 (en) * 2000-03-24 2002-08-01 Susan Schia Vi Oncogenic osteomalacia-related gene 1
US20020028465A1 (en) * 2000-05-03 2002-03-07 John Bertin Novel molecules of the NBS/LRR protein family and uses thereof
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
AU2001266844A1 (en) * 2000-06-09 2001-12-17 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
AU2001287639A1 (en) 2000-07-28 2002-02-13 Ulrich Wissenbach Trp8, trp9 and trp10, markers for cancer
EP1317530A2 (en) * 2000-09-08 2003-06-11 Millennium Pharmaceuticals, Inc. 27877, a phospholipase and uses therefor
CA2425643A1 (en) * 2000-10-11 2002-04-18 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7119185B2 (en) * 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
WO2002066623A2 (en) * 2001-02-21 2002-08-29 Bayer Aktiengesellschaft Regulation of human phosphatidic acid-preferring phospholipase a1
WO2002081642A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
EP1383922A4 (en) 2001-04-10 2005-03-30 Agensys Inc Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2002308139A1 (en) * 2001-04-12 2002-10-28 Bayer Aktiengesellschaft Regulation of human methionine aminopeptidase-like protein
US7335467B2 (en) * 2001-05-15 2008-02-26 Ludwig Institute For Cancer Research Breast cancer antigens
WO2003057870A1 (en) * 2002-01-07 2003-07-17 Bayer Healthcare Ag Human phosphatidic acid phosphatase type 2-like protein
ATE545651T1 (en) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic VECTORS FOR EXPRESSING HML-2 POLYPEPTIDES
US20040121362A1 (en) 2002-06-20 2004-06-24 Whitney Gena S. Identification and modulation of a G-protein coupled receptor (GPCR), RAI-3, associated with chronic obstructive pulmonary disease (COPD) and NF-kappaB and E-selectin regulation
US20060189518A1 (en) * 2002-06-26 2006-08-24 Takeda Pharmaceutical Company Limited Preventing/remedies for cancer
JP2006514823A (en) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク Compositions, kits and methods for identifying, evaluating, preventing and treating cervical cancer
ES2353384T3 (en) 2003-02-12 2011-03-01 Georgetown University USE OF ARTEMISININE TO TREAT INDUCED TUMORS BY ONCOGENIC VIRUSES AND TO TREAT VIVIC INFECTIONS.
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
EP1692260A2 (en) * 2003-10-06 2006-08-23 Centocor, Inc. Hypoxia - responsive human cngh-0002 genes and polypeptides
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006063065A2 (en) 2004-12-08 2006-06-15 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005967A1 (en) * 1996-08-05 1998-02-12 Quantum Biosystems Ltd., In Creditors' Voluntary Liquidation, Acting By Its Liquidator, Roger William Gillett Of Crane & Partners Assessment of cervical cells
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005967A1 (en) * 1996-08-05 1998-02-12 Quantum Biosystems Ltd., In Creditors' Voluntary Liquidation, Acting By Its Liquidator, Roger William Gillett Of Crane & Partners Assessment of cervical cells
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HTG EMBL; 30 August 1999 (1999-08-30), BIRREN, B. ET AL.: "Homo sapiens chromosome 15 clone RP11-16B9 map 15", XP002175250 *
DATABASE EM_HUM EMBL; 2 November 1999 (1999-11-02), HEILIG, R. ET AL.: "Human chromosome 14 DNA sequence BAC R-307P22 of library RPCI-11", XP002175251 *
NIELSEN H ET AL: "IDENTIFICATION OF PROKARYOTIC AND EUKARYOTIC SIGNAL PEPTIDES AND PREDICTION OF THEIR CLEAVAGE SITES", PROTEIN ENGINEERING, vol. 10, no. 1, 1997, pages 1 - 6, XP002072638, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
AU2074201A (en) 2001-06-18
WO2001042467A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2002101075A9 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2003265556A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
WO2002028432A3 (en) Stem cell-based methods for preventing and treating tumor
WO2002044419A3 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP